Emily Bertsch
Adult Health · Pensacola, FLNPI 1356869267
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 80 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $819, 6.0 times the $137 reported in 2023.
Across 80 payments — averaging $18.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$233
- Incyte Corporation$139
- Genentech USA, Inc.$116
- Merck$114
- Takeda Pharmaceuticals U.S.A., Inc.$74
- Sanofi$71
- plus $770 from 24 others
What the payments were for
- Food & beverage$1,518100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 11 | $233 |
| Incyte Corporation | 7 | $139 |
| Genentech USA, Inc. | 6 | $116 |
| Merck | 6 | $114 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $74 |
| Sanofi | 4 | $71 |
| Jazz Pharmaceuticals Inc. | 3 | $70 |
| Johnson & Johnson | 4 | $68 |
| Daiichi Sankyo Inc. | 3 | $56 |
| Eisai Inc. | 3 | $53 |
| E.r. Squibb & Sons, L.L.C. | 3 | $50 |
| Pfizer | 3 | $46 |
| AVEO Pharmaceuticals, Inc. | 2 | $39 |
| AstraZeneca | 2 | $37 |
| ADC Therapeutics America, Inc. | 2 | $33 |
| Bristol Myers Squibb | 1 | $33 |
| Array Biopharma Inc | 2 | $31 |
| Genmab U.S., Inc. | 2 | $29 |
| Stemline Therapeutics Inc. | 1 | $23 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
| Bayer | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Boston Scientific | 1 | $19 |
| Pharmacosmos Therapeutics Inc. | 1 | $19 |
| Beigene USA, Inc. | 1 | $19 |
| AbbVie | 1 | $18 |
| GSK | 1 | $17 |
| Syndax Pharmaceuticals, Inc. | 1 | $15 |
| Beone Medicines USA, Inc. | 1 | $15 |
| EMD Serono, Inc. | 1 | $15 |
How this compares
$1,518 in reported general payments places this provider in the 70th percentile of 2,237 adult health providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omeprazole | 12 | $94 |
Paid to pharmacies, not to this prescriber.
Other adult health in Pensacola
- Joshua WingPensacola$11K
- Patricia PagnottaMaitland$409K
- Carly KoelschSarasota$265K
- Norma SolisMiami$150K
- Ashley PontenbergWinter Park$136K
- Jeffrey HernandezMiami$122K
- Jamie JohnsonTampa$58K
- Jessica MangesClearwater$52K
- Sita SwamyOrlando$49K
- Cynthia OteroMaitland$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.